⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Home/Drugs/Pemvidutide

Pemvidutide

Pemvidutide

Phase 2b

Sponsor: Altimmune

Indication: MASH / Obesity

Mechanism of Action

GLP-1/Glucagon Dual Agonist

Target: GLP-1Target: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05006885

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase:PHASE1Org:Altimmune, Inc.

COMPLETED

Relevant Publications (PubMed)

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.

Patil S, Jha N, Jha MK

Addict Behav Rep2026 Jun

Systemic Pharmacokinetic Principles of Therapeutic Peptides.

Nordell P, Jansson-Löfmark R, Gennemark P

Clin Pharmacokinet2026 Feb 9

Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.

von Haehling S, Sato R, Langer H et al.

J Cachexia Sarcopenia Muscle2025 Dec

The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.

Validated Models

This drug has been validated in the following preclinical models:

NCT05292911

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase:PHASE1Org:Altimmune, Inc.

COMPLETEDNCT04972396

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Phase:PHASE1Org:Altimmune, Inc.

RECRUITINGNCT07009860

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Phase:PHASE2Org:Altimmune, Inc.

ACTIVE_NOT_RECRUITINGNCT06987513

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Phase:PHASE2Org:Altimmune, Inc.

View all trials on ClinicalTrials.gov

Tacke F

Lancet2025 Dec 6

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.

Noureddin M, Harrison SA, Loomba R et al.

Lancet2025 Dec 6

View more on PubMed